Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists.

[1]  R. Ingram,et al.  Ventilation-Perfusion Changes after Aerosolized Isoproterenol in Asthma1, 2 , 2015 .

[2]  M. Cazzola,et al.  Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. , 2007, Pulmonary pharmacology & therapeutics.

[3]  M. Cazzola,et al.  Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. , 2006, Respiratory medicine.

[4]  H. Magnussen,et al.  Onset and Duration of Action of Formoterol and Tiotropium in Patients with Moderate to Severe COPD , 2006, Respiration.

[5]  J. V. van Noord,et al.  Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.

[6]  M. Cazzola,et al.  Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. , 2006, Respiratory medicine.

[7]  M. Cazzola,et al.  An Acute Bronchodilator Test with Tiotropium or Salmeterol Does Not Allow a Subdivision of Patients according to Responses , 2005, Respiration.

[8]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[9]  M. Cazzola,et al.  The functional impact of adding salmeterol and tiotropium in patients with stable COPD. , 2004, Respiratory medicine.

[10]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[11]  M. Cazzola,et al.  The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.

[12]  C. Boshoff,et al.  Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD , 2003, Thorax.

[13]  Y. Kwan,et al.  Role of Na+/H+ exchanger in acetylcholine-mediated pulmonary artery contraction of spontaneously hypertensive rats. , 2003, European journal of pharmacology.

[14]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[15]  Y. Kwan,et al.  Role of mitogen-activated protein kinase pathway in acetylcholine-mediated in vitro relaxation of rat pulmonary artery. , 2002, European journal of pharmacology.

[16]  J. Innes,et al.  Short term variability of single breath carbon monoxide transfer factor , 2001, Thorax.

[17]  N. Gross,et al.  Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. , 1999, American journal of respiratory and critical care medicine.

[18]  Y. Castaing,et al.  Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients. , 1998, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[19]  J. Barberà,et al.  Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. , 1996, Chest.

[20]  J. Karpel,et al.  A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. , 1990, Chest.

[21]  C. Clelland,et al.  Impairment of pulmonary endothelium‐dependent relaxation in patients with Eisenmenger's syndrome , 1990, British journal of pharmacology.

[22]  C. Ringsted,et al.  Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease. Effects of terbutaline administration. , 1989, Chest.

[23]  P. Barnes,et al.  Muscarinic receptor subtypes mediating vasodilation in the pulmonary artery. , 1988, European journal of pharmacology.

[24]  C. Huynh,et al.  How Does Salbutamol Improve the Ventricular Performance in Patients with Chronic Obstructive Pulmonary Disease? , 1988, Journal of cardiovascular pharmacology.

[25]  N. Gross,et al.  Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent. , 1987, The American review of respiratory disease.

[26]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[27]  W. MacNee,et al.  Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. , 1983, British medical journal.

[28]  G. Teule,et al.  Haemodynamic effects of terbutaline in chronic obstructive airways disease. , 1980, Thorax.

[29]  D. Schlueter,et al.  Double blind comparison of acute bronchial and ventilation-perfusion changes to atrovent and isoproterenol. , 1978, Chest.

[30]  R. Knudson,et al.  An effect of isoproterenol on ventilation-perfusion in asthmatic versus normal subjects , 1967 .

[31]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[32]  C. Cooper,et al.  The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.

[33]  L. Reid,et al.  Mapping of β-Adrenergic Receptors in Rat Lung: Effect of Isoproterenol , 1984 .